Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Immunotherapy & Biofluid Biopsies 2016

Cancer Immunotherapy & Biofluid Biopsies 2016



Keynote Speakers


Konstantinos Aprilakis
Biotechnology Equity Research, JMP Securities, LLC


Ellen Beasley
Senior Vice President, Genomic Health Inc


Christine Biron
Esther Elizabeth Brintzenhoff Professor of Medical Science, Professor of Molecular Microbiology and Immunology, Brown University


E Antonio Chiocca
Professor and Chairman, Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School


David Fabrizio
Leader, Cancer Immunotherapy, Foundation Medicine


Gordon Freeman
Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School


Tony Godfrey
Associate Chair – Research, Department of Surgery, Boston University Medical Center


David Hafler
William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, Yale University


Malini Harigopal
Associate Professor, Dept of Pathology, Breast and Cytopathology, Yale University


Shana Kelley
Professor, University Of Toronto


Fred Kramer
Professor of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School Rutgers University


Cloud Paweletz
Head of the Translational Research Laboratory, Dana Farber Cancer Institute


Johan Skog
Chief Scientific Officer, Exosome Diagnostics Inc


Paul Song
Chief Medical Officer, Cynvenio Biosystems


Gary S Stein
Professor and Chairperson, Department of Biochemistry, Director, University of Vermont Cancer Center


AmirAli Talasaz
Co-Founder, President & COO, Guardant Health


Abraham Tzou
Medical Officer, Food and Drug Administration (FDA/CDRH)

Overview

Cancer Immunotherapy represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo.  There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

Biofluid Biopsies represents the harvest of circulating biomarkers to monitor progression of disease especially in cancer.  The minimally-invasive means of capture of circulating-free DNA (cfDNA), circulating tumor cells (CTCs), circulating proteins and circulating extracellular vesicles (EVs) represents a new paradigm for longitudinal monitoring of disease and therapy progression.

Cancer Immunotherapy & Biofluid Biopsies 2016 brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics.  This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.

Agenda Topics

  • Biomarkers & Companion Diagnostics for Immunotherapy
  • Checkpoint and Non-Checkpoint Immunotherapies
  • Chimeric Antigen Receptor (CAR) T-Cells in Cancer Immunotherapy
    • CAR T-Cell Design
  • Circulating Biomarkers for Monitoring Disease Progression and Treatment Outcomes
    • Circulating Cell-Free DNA (cfDNA)
    • Circulating Tumor Cells (CTCs)
    • Extracellular Vesicles (EVs): Exosomes and Microvesicles as Circulating Biomarker Carriers
  • Combination Cancer Immunotherapy
  • Costimulatory Molecules for Immunological Activation & Therapeutic Intervention
    • CD28 and others
  • Immunomodulatory Antibodies
  • Liquid Biopsies for Minimally-Invasive Diagnostics
  • Natural Killer (NK) Cells in Cancer Immunotherapy
  • New and Emerging Targets for Immunological Intervention in Cancer
    • PD-1/PDL-1
  • Oncolytic Viruses as Cancer Immunotherapeutics
  • Peptide Vaccines
  • Preclinical Animal Models for Immuno-Oncology
  • Small Molecules in Cancer Immune Therapy
    • Clinical Results
    • Mechanisms of Action
  • Targeting Signaling Pathways in Cancer as Therapeutic Intervention
  • Targeting the Tumor Microenvironment

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager
jeff@selectbioconferences.com
+1-510-857-4865

Distinguished Faculty

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute
Nikhil Joshi, Assistant Professor of Immunobiology, Yale University
Alain Charest, Associate Professor, Beth Israel Deaconess Medical Center, Cancer Research Institute, Department of Medicine, Harvard Medical School
Brian Dougherty, Director, Translational Genomics, AstraZeneca Oncology
Thomas-Oliver Kleen, Executive VP Immune Monitoring, Epiontis GmbH
Francesco Marangoni, Instructor in Medicine, Massachusetts General Hospital/Harvard Medical School
Leonora Balaj, Instructor in Neurology, Mass General Hospital (MGH)/Harvard Medical School
Galina Gabriely, Instructor, Department of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital
Stephen Kirk, Non-Clinical Immunotoxicologist, Covance Laboratories Ltd
Brian Miller, Oncology Fellow, Dana-Farber Cancer Institute
Louis Messina, Professor and Chief Division od Vascular and Endovascular Surgery, Vice Chair Department of Surgery, University of Massachusetts Medical School
Raymond Welsh, Professor Emeritus, University of Massachusetts Medical School
Carmen Gerlach, Researcher, Harvard Medical School


Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks